Approaches to risk-benefit assessment of seafood consumption: lessons learned from an evidence scan

被引:1
|
作者
Farakos, Sofia M. Santillana [1 ]
Heilman, Jacqueline [1 ]
Abt, Eileen [1 ]
Dennis, Sherri [1 ]
机构
[1] US FDA, Ctr Food Safety & Appl Nutr, College Pk, MD 20740 USA
来源
FRONTIERS IN NUTRITION | 2024年 / 11卷
关键词
risk-benefit; risk analysis; RBA; fish; risk management; FISH;
D O I
10.3389/fnut.2024.1290680
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Qualitative and quantitative risk-benefit assessments (RBA) can be used to support public health decisions in food safety. We conducted an evidence scan to understand the state of the science regarding RBA in seafood to help inform seafood dietary advice in the United States. We collected published RBA studies assessing seafood consumption, designed inclusion and exclusion criteria to screen these studies, and conducted systematic data extraction for the relevant studies published since 2019. Our findings indicate the selection of health risks and benefits does not generally follow a systematic approach. Uncertainty and variability in RBAs is often not addressed, and quantitative RBAs making use of a single health metric generally have not been leveraged to directly support published regulatory decisions or dietary guidance. To elevate the role of RBA in supporting regulatory decision-making, risk assessors and risk managers must work together to set expectations and goals. We identified the need for a prioritization phase (e.g., multicriteria decision analysis model) to determine the risks and benefits of greatest public health impact to inform the RBA design. This prioritization would consider not only the degree of public health impact of each risk and benefit, but also the potential for risks and benefits to converge on common health outcomes and their importance to subpopulations. Including a prioritization could improve the utility of the RBAs to better inform risk management decisions and advance public health. Our work serves to guide the United States Food and Drug Administration's approaches to RBA in foods.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] THE RISK-BENEFIT ASSESSMENT OF ANTIDEPRESSANT DRUGS
    HENRY, JA
    MARTIN, AJ
    MEDICAL TOXICOLOGY AND ADVERSE DRUG EXPERIENCE, 1987, 2 (06): : 445 - 462
  • [22] Alternative approaches to risk-benefit balancing in immunotherapy
    Ilhan, Yusuf
    Ergun, Yakup
    LANCET ONCOLOGY, 2024, 25 (05): : e178 - e178
  • [23] A RISK-BENEFIT ASSESSMENT OF TACROLIMUS IN TRANSPLANTATION
    WINKLER, M
    CHRISTIANS, U
    DRUG SAFETY, 1995, 12 (05) : 348 - 357
  • [24] A risk-benefit assessment of abciximab in angioplasty
    Kleiman, NS
    DRUG SAFETY, 1999, 20 (01) : 43 - 57
  • [25] A RISK-BENEFIT ASSESSMENT OF TAMOXIFEN THERAPY
    CATHERINO, WH
    JORDAN, VC
    DRUG SAFETY, 1993, 8 (05) : 381 - 397
  • [26] Clinical equipoise and risk-benefit assessment
    Miller, Franklin G.
    CLINICAL TRIALS, 2012, 9 (05) : 621 - 627
  • [27] A PRELIMINARY RISK-BENEFIT ASSESSMENT OF PACLITAXEL
    BITTON, RJ
    FIGG, WD
    REED, E
    DRUG SAFETY, 1995, 12 (03) : 196 - 208
  • [28] RISK-BENEFIT ASSESSMENT OF CARBAMAZEPINE IN CHILDREN
    SEETHARAM, MN
    PELLOCK, JM
    DRUG SAFETY, 1991, 6 (02) : 148 - 158
  • [29] A risk-benefit assessment of amifostine in cytoprotection
    Mabro, M
    Faivre, S
    Raymond, E
    DRUG SAFETY, 1999, 21 (05) : 367 - 387
  • [30] A risk-benefit assessment of antileukotrienes in asthma
    Smith, LJ
    DRUG SAFETY, 1998, 19 (03) : 205 - 218